BACKGROUND: The validity of the KRAS mutation as a predictor of recurrence-free survival (RFS) or overall survival (OS) is unclear. The current study investigated whether the presence of the KRAS mutation decreased RFS or OS in patients with colorectal cancer who underwent liver resection. METHODS: Patients with resected colorectal liver metastases who received adjuvant hepatic arterial infusion plus systemic therapy and for whom KRAS data was available were evaluated. Correlation between KRAS and clinical factors was done using the Fisher exact test. Kaplan-Meier methods were used to estimate the median RFS and OS. RESULTS: A total of 169 patients were evaluated, 118 of whom had KRAS wild-type (WT) and 51 had KRAS mutated (MUT) tumors. The 3-year RFS rate was 46% for patients with KRAS WT (95% confidence interval [95% CI], 35%-56%) and 30% (95% CI, 16%-44%) for patients with KRAS MUT (P =.005). The 3-year OS rate was 95% (95% CI, 87%-98%) and 81% (95% CI, 62%-95%), respectively, for patients with KRAS WT and KRAS MUT (P =.07). On multivariate analysis, KRAS remained a significant predictor of RFS (hazard ratio, 1.9). The 3-year cumulative recurrence rate by site of metastases was as follows: 2% versus 13.4% for bone (P≤.01), 2% versus 14.5% for brain (P =.05), 33.2% versus 58% for lung (P≤.01), and 30% versus 47% for liver (P =.10) in patients with KRAS WT versus KRAS MUT. CONCLUSIONS: In the current study, among patients with resected colorectal liver metastases who were treated with adjuvant hepatic arterial infusion plus systemic therapy, patients with KRAS MUT were found to have a significantly worse 3-year RFS (30%) compared with KRAS WT (46%) p=.005. The cumulative incidence of bone, brain, and lung metastases was significantly higher for patients with KRAS MUT compared with those with KRAS WT.
BACKGROUND: The validity of the KRAS mutation as a predictor of recurrence-free survival (RFS) or overall survival (OS) is unclear. The current study investigated whether the presence of the KRAS mutation decreased RFS or OS in patients with colorectal cancer who underwent liver resection. METHODS:Patients with resected colorectal liver metastases who received adjuvant hepatic arterial infusion plus systemic therapy and for whom KRAS data was available were evaluated. Correlation between KRAS and clinical factors was done using the Fisher exact test. Kaplan-Meier methods were used to estimate the median RFS and OS. RESULTS: A total of 169 patients were evaluated, 118 of whom had KRAS wild-type (WT) and 51 had KRAS mutated (MUT) tumors. The 3-year RFS rate was 46% for patients with KRAS WT (95% confidence interval [95% CI], 35%-56%) and 30% (95% CI, 16%-44%) for patients with KRAS MUT (P =.005). The 3-year OS rate was 95% (95% CI, 87%-98%) and 81% (95% CI, 62%-95%), respectively, for patients with KRAS WT and KRAS MUT (P =.07). On multivariate analysis, KRAS remained a significant predictor of RFS (hazard ratio, 1.9). The 3-year cumulative recurrence rate by site of metastases was as follows: 2% versus 13.4% for bone (P≤.01), 2% versus 14.5% for brain (P =.05), 33.2% versus 58% for lung (P≤.01), and 30% versus 47% for liver (P =.10) in patients with KRAS WT versus KRAS MUT. CONCLUSIONS: In the current study, among patients with resected colorectal liver metastases who were treated with adjuvant hepatic arterial infusion plus systemic therapy, patients with KRAS MUT were found to have a significantly worse 3-year RFS (30%) compared with KRAS WT (46%) p=.005. The cumulative incidence of bone, brain, and lung metastases was significantly higher for patients with KRAS MUT compared with those with KRAS WT.
Authors: Hemanth J Varghese; Melanie T M Davidson; Ian C MacDonald; Sylvia M Wilson; Kishore V Nadkarni; Alan C Groom; Ann F Chambers Journal: Cancer Res Date: 2002-02-01 Impact factor: 12.701
Authors: Efsevia Vakiani; Manickam Janakiraman; Ronglai Shen; Rileen Sinha; Zhaoshi Zeng; Jinru Shia; Andrea Cercek; Nancy Kemeny; Michael D'Angelica; Agnes Viale; Adriana Heguy; Philip Paty; Timothy A Chan; Leonard B Saltz; Martin Weiser; David B Solit Journal: J Clin Oncol Date: 2012-06-04 Impact factor: 44.544
Authors: Jeanne Tie; Lara Lipton; Jayesh Desai; Peter Gibbs; Robert N Jorissen; Michael Christie; Katharine J Drummond; Benjamin N J Thomson; Valery Usatoff; Peter M Evans; Adrian W Pick; Simon Knight; Peter W G Carne; Roger Berry; Adrian Polglase; Paul McMurrick; Qi Zhao; Dana Busam; Robert L Strausberg; Enric Domingo; Ian P M Tomlinson; Rachel Midgley; David Kerr; Oliver M Sieber Journal: Clin Cancer Res Date: 2011-01-14 Impact factor: 12.531
Authors: M Margaret Kemeny; Sudeshna Adak; Bruce Gray; John S Macdonald; Thomas Smith; Stuart Lipsitz; Elin R Sigurdson; Peter J O'Dwyer; Al B Benson Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: H J Andreyev; A R Norman; D Cunningham; J Oates; B R Dix; B J Iacopetta; J Young; T Walsh; R Ward; N Hawkins; M Beranek; P Jandik; R Benamouzig; E Jullian; P Laurent-Puig; S Olschwang; O Muller; I Hoffmann; H M Rabes; C Zietz; C Troungos; C Valavanis; S T Yuen; J W Ho; C T Croke; D P O'Donoghue; W Giaretti; A Rapallo; A Russo; V Bazan; M Tanaka; K Omura; T Azuma; T Ohkusa; T Fujimori; Y Ono; M Pauly; C Faber; R Glaesener; A F de Goeij; J W Arends; S N Andersen; T Lövig; J Breivik; G Gaudernack; O P Clausen; P D De Angelis; G I Meling; T O Rognum; R Smith; H S Goh; A Font; R Rosell; X F Sun; H Zhang; J Benhattar; L Losi; J Q Lee; S T Wang; P A Clarke; S Bell; P Quirke; V J Bubb; J Piris; N R Cruickshank; D Morton; J C Fox; F Al-Mulla; N Lees; C N Hall; D Snary; K Wilkinson; D Dillon; J Costa; V E Pricolo; S D Finkelstein; J S Thebo; A J Senagore; S A Halter; S Wadler; S Malik; K Krtolica; N Urosevic Journal: Br J Cancer Date: 2001-09-01 Impact factor: 7.640
Authors: Yoshikuni Kawaguchi; Scott Kopetz; Timothy E Newhook; Mario De Bellis; Yun Shin Chun; Ching-Wei D Tzeng; Thomas A Aloia; Jean-Nicolas Vauthey Journal: Clin Cancer Res Date: 2019-06-20 Impact factor: 12.531
Authors: Andrea Cercek; Maria Ignez Braghiroli; Joanne F Chou; Jaclyn F Hechtman; Nancy Kemeny; Leonard Saltz; Marinela Capanu; Rona Yaeger Journal: Clin Cancer Res Date: 2017-04-26 Impact factor: 12.531
Authors: Timothy L Frankel; Efsevia Vakiani; Hari Nathan; Ronald P DeMatteo; T Peter Kingham; Peter J Allen; William R Jarnagin; Nancy E Kemeny; David B Solit; Michael I D'Angelica Journal: Cancer Date: 2016-10-13 Impact factor: 6.860
Authors: Linda M Pak; Nancy E Kemeny; Marinela Capanu; Joanne F Chou; Taryn Boucher; Andrea Cercek; Vinod P Balachandran; T Peter Kingham; Peter J Allen; Ronald P DeMatteo; William R Jarnagin; Michael I D'Angelica Journal: J Surg Oncol Date: 2017-11-22 Impact factor: 3.454
Authors: Yoshikuni Kawaguchi; Heather A Lillemoe; Elena Panettieri; Yun Shin Chun; Ching-Wei D Tzeng; Thomas A Aloia; Scott Kopetz; Jean-Nicolas Vauthey Journal: J Am Coll Surg Date: 2019-05-02 Impact factor: 6.113
Authors: Rona Yaeger; Elizabeth Cowell; Joanne F Chou; Alexandra N Gewirtz; Laetitia Borsu; Efsevia Vakiani; David B Solit; Neal Rosen; Marinela Capanu; Marc Ladanyi; Nancy Kemeny Journal: Cancer Date: 2014-12-09 Impact factor: 6.860